Company intelligence / Profile preview

PAGE Therapeutics AG

Basel, Basel-Stadt, Switzerlandpagetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PAGE Therapeutics has demonstrated, via an academic clinical study published in Nature Medicine, that the cardiotonic agent digoxin can significantly reduce the size of circulating tumor cell clusters in metastatic breast cancer patients. The company holds exclusive rights to use digoxin and other Na+/K+ ATPase inhibitors for metastasis prevention/treatment and is developing proprietary compounds with higher activity than digoxin, currently showing promising results in preclinical models[2].

Therapeutic areas: Oncology
Modalities: Small molecules (including Na+/K+ ATPase inhibitors)Proprietary compounds targeting circulating tumor cell clusters[2][3]
Industry: Biotech

Partnerships

ETH Zurich (spin-out origin and ongoing scientific collaboration)[2]

Beyond the preview

Go deeper on PAGE Therapeutics AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAGE Therapeutics AG.

Explore the full profile